230 related articles for article (PubMed ID: 28237968)
1. Nationwide experience of catecholaminergic polymorphic ventricular tachycardia caused by RyR2 mutations.
Broendberg AK; Nielsen JC; Bjerre J; Pedersen LN; Kristensen J; Henriksen FL; Bundgaard H; Jensen HK
Heart; 2017 Jun; 103(12):901-909. PubMed ID: 28237968
[TBL] [Abstract][Full Text] [Related]
2. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.
Sy RW; Gollob MH; Klein GJ; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Gow RM; Green MS; Birnie DH; Krahn AD
Heart Rhythm; 2011 Jun; 8(6):864-71. PubMed ID: 21315846
[TBL] [Abstract][Full Text] [Related]
3. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives.
van der Werf C; Nederend I; Hofman N; van Geloven N; Ebink C; Frohn-Mulder IM; Alings AM; Bosker HA; Bracke FA; van den Heuvel F; Waalewijn RA; Bikker H; van Tintelen JP; Bhuiyan ZA; van den Berg MP; Wilde AA
Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):748-56. PubMed ID: 22787013
[TBL] [Abstract][Full Text] [Related]
4. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.
Priori SG; Napolitano C; Memmi M; Colombi B; Drago F; Gasparini M; DeSimone L; Coltorti F; Bloise R; Keegan R; Cruz Filho FE; Vignati G; Benatar A; DeLogu A
Circulation; 2002 Jul; 106(1):69-74. PubMed ID: 12093772
[TBL] [Abstract][Full Text] [Related]
5. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.
Gray B; Bagnall RD; Lam L; Ingles J; Turner C; Haan E; Davis A; Yang PC; Clancy CE; Sy RW; Semsarian C
Heart Rhythm; 2016 Aug; 13(8):1652-60. PubMed ID: 27157848
[TBL] [Abstract][Full Text] [Related]
6. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
[TBL] [Abstract][Full Text] [Related]
7. Exon 3 deletion of RYR2 encoding cardiac ryanodine receptor is associated with left ventricular non-compaction.
Ohno S; Omura M; Kawamura M; Kimura H; Itoh H; Makiyama T; Ushinohama H; Makita N; Horie M
Europace; 2014 Nov; 16(11):1646-54. PubMed ID: 24394973
[TBL] [Abstract][Full Text] [Related]
8. Non-ventricular, Clinical, and Functional Features of the RyR2(R420Q) Mutation Causing Catecholaminergic Polymorphic Ventricular Tachycardia.
Domingo D; Neco P; Fernández-Pons E; Zissimopoulos S; Molina P; Olagüe J; Suárez-Mier MP; Lai FA; Gómez AM; Zorio E
Rev Esp Cardiol (Engl Ed); 2015 May; 68(5):398-407. PubMed ID: 25440180
[TBL] [Abstract][Full Text] [Related]
9. Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia.
Wangüemert Pérez F; Hernández Afonso JS; Groba Marco MDV; Caballero Dorta E; Álvarez Acosta L; Campuzano Larrea O; Pérez G; Brugada Terradellas J; Brugada Terradellas R
Rev Esp Cardiol (Engl Ed); 2018 Mar; 71(3):185-191. PubMed ID: 28789916
[TBL] [Abstract][Full Text] [Related]
10. Sudden death after inappropriate shocks of implantable cardioverter defibrillator in a catecholaminergic polymorphic ventricular tachycardia case with a novel RyR2 mutation.
Itoh H; Murayama T; Kurebayashi N; Ohno S; Kobayashi T; Fujii Y; Watanabe M; Ogawa H; Anzai T; Horie M
J Electrocardiol; 2021; 69():111-118. PubMed ID: 34656916
[TBL] [Abstract][Full Text] [Related]
11. Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia.
Wangüemert F; Bosch Calero C; Pérez C; Campuzano O; Beltran-Alvarez P; Scornik FS; Iglesias A; Berne P; Allegue C; Ruiz Hernandez PM; Brugada J; Pérez GJ; Brugada R
Heart Rhythm; 2015 Jul; 12(7):1636-43. PubMed ID: 25814417
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome.
Roston TM; Wei J; Guo W; Li Y; Zhong X; Wang R; Estillore JP; Peltenburg PJ; Noguer FRI; Till J; Eckhardt LL; Orland KM; Hamilton R; LaPage MJ; Krahn AD; Tadros R; Vinocur JM; Kallas D; Franciosi S; Roberts JD; Wilde AAM; Jensen HK; Sanatani S; Chen SRW
JAMA Cardiol; 2022 Jan; 7(1):84-92. PubMed ID: 34730774
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and mutational analysis of the RyR2 gene in seven Czech families with catecholaminergic polymorphic ventricular tachycardia.
Andrsova I; Valaskova I; Kubus P; Vit P; Gaillyova R; Kadlecova J; Manouskova L; Novotny T
Pacing Clin Electrophysiol; 2012 Jul; 35(7):798-803. PubMed ID: 22519458
[TBL] [Abstract][Full Text] [Related]
14. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
[TBL] [Abstract][Full Text] [Related]
15. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients.
Postma AV; Denjoy I; Kamblock J; Alders M; Lupoglazoff JM; Vaksmann G; Dubosq-Bidot L; Sebillon P; Mannens MM; Guicheney P; Wilde AA
J Med Genet; 2005 Nov; 42(11):863-70. PubMed ID: 16272262
[TBL] [Abstract][Full Text] [Related]
16. Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene.
Nof E; Belhassen B; Arad M; Bhuiyan ZA; Antzelevitch C; Rosso R; Fogelman R; Luria D; El-Ani D; Mannens MM; Viskin S; Eldar M; Wilde AA; Glikson M
Heart Rhythm; 2011 Oct; 8(10):1546-52. PubMed ID: 21699856
[TBL] [Abstract][Full Text] [Related]
17. Genealogy and clinical course of catecholaminergic polymorphic ventricular tachycardia caused by the ryanodine receptor type 2 P2328S mutation.
Koponen M; Marjamaa A; Tuiskula AM; Viitasalo M; Nallinmaa-Luoto T; Leinonen JT; Widen E; Toivonen L; Kontula K; Swan H
PLoS One; 2020; 15(12):e0243649. PubMed ID: 33315912
[TBL] [Abstract][Full Text] [Related]
18. The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: findings from an international multicentre registry.
Roston TM; Yuchi Z; Kannankeril PJ; Hathaway J; Vinocur JM; Etheridge SP; Potts JE; Maginot KR; Salerno JC; Cohen MI; Hamilton RM; Pflaumer A; Mohammed S; Kimlicka L; Kanter RJ; LaPage MJ; Collins KK; Gebauer RA; Temple JD; Batra AS; Erickson C; Miszczak-Knecht M; Kubuš P; Bar-Cohen Y; Kantoch M; Thomas VC; Hessling G; Anderson C; Young ML; Choi SHJ; Cabrera Ortega M; Lau YR; Johnsrude CL; Fournier A; Van Petegem F; Sanatani S
Europace; 2018 Mar; 20(3):541-547. PubMed ID: 28158428
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers.
Mazzanti A; Kukavica D; Trancuccio A; Memmi M; Bloise R; Gambelli P; Marino M; Ortíz-Genga M; Morini M; Monteforte N; Giordano U; Keegan R; Tomasi L; Anastasakis A; Davis AM; Shimizu W; Blom NA; Santiago DJ; Napolitano C; Monserrat L; Priori SG
JAMA Cardiol; 2022 May; 7(5):504-512. PubMed ID: 35353122
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a novel mutation in the cardiac ryanodine receptor that results in catecholaminergic polymorphic ventricular tachycardia.
Jiang D; Jones PP; Davis DR; Gow R; Green MS; Birnie DH; Chen SR; Gollob MH
Channels (Austin); 2010; 4(4):302-10. PubMed ID: 20676041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
